Kepos Capital’s Aspire Biopharma Warrant ASBPW Stock Holding History

Kepos Capital’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-350,000	Closed	-$18K	–	323
2023 Q2	$18K	Buy	+350,000	New	+$12.8K	﹤0.01%	290
2022 Q4	$28K	Hold	350,000	–	–	﹤0.01%	296
2022 Q3	$39K	Hold	350,000	–	–	﹤0.01%	311
2022 Q2	$60K	Buy	+350,000	New	+$76.1K	0.01%	314

Other funds holding ASBPW

Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Kepos Capital's ASBPW Position: Q3 2023 in Review

Kepos Capital sold out of Aspire Biopharma Warrant (ASBPW) in Q3 2023, closing a stake of 350,000 shares — an estimated $18K sold.

Kepos Capital first reported a position in ASBPW in Q2 2022 and held it in 4 quarters. The position peaked at $60K in Q2 2022. 39 funds tracked by Wall St. Rank hold ASBPW as of Q3 2023.

Kepos Capital reported no remaining Aspire Biopharma Warrant position as of Q3 2023 after selling out during the quarter.
Kepos Capital sold 350,000 Aspire Biopharma Warrant shares in Q3 2023, an estimated $18K.
Kepos Capital first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 4 quarters.
Kepos Capital's Aspire Biopharma Warrant position peaked at $60K in Q2 2022.
39 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q3 2023.

Based on Kepos Capital's 13F filing for Q3 2023, filed 14 Nov 2023.